ClinicalTrials.gg

Program

belumosudil

Also written as “Belumosudil”, “Belumosudil (KD025)” and “Belumosudil mesylate”.

Its studies are mostly in Bronchiolitis Obliterans Syndrome · Immune System Diseases · Scleroderma, Diffuse · Autoimmune Diseases · Psoriasis, led by 2 companies.

Furthest: phase 4, since Sep 24, 202426 company-led studies, 6 open or runningNext primary completion: Jan 26, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi256 open or runningphase 4since Sep 24, 2024Apr 2, 2014Jan 26, 2027phase 1 · NCT07726914
BioNova Pharmaceuticals (Shanghai)10 open or runningphase 2since Jun 11, 2021Jun 11, 2021none ahead

Also a collaborator on its studies: meiji-seika-pharma-co-ltd and quotient-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Apr 2, 2014.

  1. Dec 11, 2020Phase 2 study in Scleroderma, DiffuseSanofi · NCT04680975 · 10 enrolled · United States
  2. Jan 13, 2021Early phase 1 study in Healthy VolunteersSanofi · NCT04735822 · 30 enrolled · United Kingdom
  3. Jun 11, 2021BioNova Pharmaceuticals (Shanghai)'s first study: phase 2 study in Bronchiolitis Obliterans SyndromeNew to BioNova Pharmaceuticals (Shanghai)BioNova Pharmaceuticals (Shanghai) · NCT04930562 · 30 enrolled · China
  4. Feb 2, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT05305989 · 23 enrolled · United States
  5. Oct 3, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT05567406
  6. Jun 15, 20233 phase 1 studies in Immune System DiseasesSanofi · NCT05918627, NCT05918614, NCT05918588
  7. Oct 7, 2023Phase 3 study in Lung Transplant RejectionSanofi · NCT06082037 · 180 planned · United States, Australia, Austria and more
  8. Nov 16, 2023Phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06143891 · 260 enrolled · United States, Argentina, Australia and more
  9. Sep 24, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06616415 · 6 enrolled · China
  10. Jul 25, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07116031 · 37 planned · United States, Belgium, Canada and more
  11. Aug 14, 2025Phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07135973 · 26 planned
  12. Jul 21, 2026Phase 1 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07726914 · 58 planned
  13. Aug 4, 2026Phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07771439 · 356 planned · Netherlands, Spain
  14. Nov 10, 2026Primary completion moved from 2026-09-28 to 2027-01-26Date moved laterphase 1 · +4 months · NCT07726914

Ahead

  1. Jan 26, 2027Primary completion: phase 1 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07726914
  2. Aug 30, 2027Primary completion: phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07135973
  3. Sep 25, 2028Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07116031
  4. Sep 29, 2028Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06143891

TargetBeta

ROCK1 →ROCK2 →read by rule
“An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), ”NCIt, by rule
“Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
netarsudilruleAlconphase 420

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07771439Bronchiolitis Obliterans Syndrome · Netherlands, Spain3RecruitingSanofiSep 14, 2029356
NCT07726914Bronchiolitis Obliterans Syndrome1Not yet recruitingSanofiJan 26, 202758
NCT07135973Bronchiolitis Obliterans Syndrome4Not yet recruitingSanofiAug 30, 202726
NCT07116031Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more2RecruitingSanofiSep 25, 202837
NCT06616415Bronchiolitis Obliterans Syndrome · China4CompletedSanofiMay 12, 20266
NCT06143891Bronchiolitis Obliterans Syndrome · United States, Argentina, Australia and more3Active, not recruitingSanofiSep 29, 2028260
NCT06082037Lung Transplant Rejection · United States, Australia, Austria and more3RecruitingSanofiJan 29, 2029180
NCT05918627Immune System Diseases · United States1CompletedSanofiDec 9, 200932
NCT05918614Immune System Diseases · United States1CompletedSanofiJun 7, 20148
NCT05918588Immune System Diseases · United States1CompletedSanofiMar 6, 201432
NCT05567406Bronchiolitis Obliterans Syndrome2WithdrawnSanofiAug 31, 20260
NCT05305989Bronchiolitis Obliterans Syndrome · United States2CompletedSanofiJun 6, 202423
NCT04930562Bronchiolitis Obliterans Syndrome · China2CompletedBioNova Pharmaceuticals (Shanghai)Jun 10, 202230
NCT04735822Healthy Volunteers · United KingdomEarly 1CompletedSanofiSep 3, 202130
NCT04680975Scleroderma, Diffuse · United States2TerminatedSanofiMay 10, 202210
NCT04166942Hepatic Impairment · United States1CompletedSanofiJun 6, 202235
NCT03907540Autoimmune Diseases · United Kingdom1CompletedSanofiMay 20, 20195
NCT03919799Scleroderma, Diffuse · United States2TerminatedSanofiAug 9, 202236
NCT03640481Bronchiolitis Obliterans Syndrome · United States2TerminatedSanofiDec 11, 2023159
NCT03530995Autoimmune Diseases · United Kingdom1CompletedSanofiFeb 8, 201973
NCT02852967Skin Diseases · United States2CompletedSanofiFeb 13, 2019110
NCT02841995Graft vs Host Disease · United States2CompletedSanofiMay 12, 202254
NCT02688647Idiopathic Pulmonary Fibrosis · United States2CompletedSanofiApr 13, 202176
NCT02557139Bioavailability · United Kingdom1CompletedSanofiOct 12, 201523
NCT02317627Psoriasis Vulgaris · United States2CompletedSanofiMar 201638
NCT02106195Psoriasis Vulgaris · United States2CompletedSanofiSep 20148

How it is read

Names in the registry

  • “Belumosudil”, 15 entries
  • “Belumosudil (KD025)”, 3 entries
  • “Belumosudil mesylate”, 3 entries
  • “KD025”, 2 entries
  • “Belumosudil 200 mg QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.